

## Learner Notification

### MED Learning Group

#### Visualizing the Mechanism of Bispecific Antibodies in NHL: Understanding Efficacy, Safety, and Applications in Refractory Disease

January 26, 2024 – January 26, 2025

Online

#### Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

#### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

#### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hours.

#### Objectives - After Attending This Program You Should Be Able To

1. Assess the latest approaches to use of novel bispecific antibody therapies for NHL.
2. Summarize current clinical data in NHL management in consideration of outcomes with bispecific antibody therapies.
3. Evaluate adverse event data associated with bispecific antibodies to inform appropriate management of potential adverse events in patients within NHL.

#### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Felecia	Beachum	NA
Daniel	DaSilva	NA
Naomi	DeBrito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Amitkumar	Mehta	Gilead, Seattle Genetics, Incyte, Morphosys/Incyte, TG Therapeutics, Kyowa Kirin, Bei Gen: Consultant; Incyte/Morphosys, BeiGen, Ipsen, Kyowa Kirin: Speakers Bureau; Incyte, Takeda, Fortyseven Inc./Gilead, Juno Pharmaceuticals/Bristol Myers Squibb, Celgene/Bristol Myers Squibb, Innate Pharmaceuticals, Seattle Genetics, TG Therapeutics: Contracted Research
Michael	Page	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)